Literature DB >> 21115406

Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of "newer" versus "classic" drugs: results of the "Compliant 2006" survey in 907 patients.

A Haag1, A Strzelczyk, S Bauer, S Kühne, H M Hamer, F Rosenow.   

Abstract

"Classic" and "newer" antiepileptic drugs (AEDs) were compared in an epidemiological survey regarding patient's acceptance of AEDs, quality of life (QoL), and employment. Data from 907 outpatients, 45.9% female (mean age: 44.8 ± 17.9 years), were evaluated by 90 neurologists in private practices, who were also involved in a non-interventional study by Sanofi-Aventis Deutschland GmbH, regarding medication, seizure type, illness duration, employment, patients' acceptance of AEDs (4-point scale where 1=very good), and QoL (6-point scale where 1=very good). Among the patients, 69.7% were on monotherapy, 25.4% were taking two AEDs, and 4.9% were taking more than two AEDs. Patient's acceptance of AEDs (mean ± SD=1.65 ± 0.62) and QoL (2.34 ± 0.89) were "good." Among patients aged 18-65 years, 68.6% were employed. QoL and acceptance were lower with polytherapy. Older age and polytherapy were associated with lower probability of employment. No differences emerged between "classic" and "newer" AED monotherapy. Polytherapy-associated lower QoL could be due to severity of illness or adverse effects of treatment.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115406     DOI: 10.1016/j.yebeh.2010.09.037

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  8 in total

1.  [Impact of early benefit assessment on patients with epilepsy in Germany: Current healthcare provision and therapeutic needs].

Authors:  A Strzelczyk; H M Hamer
Journal:  Nervenarzt       Date:  2016-04       Impact factor: 1.214

2.  Weight of epilepsy in brain tumor patients.

Authors:  Marta Maschio; Francesca Sperati; Loredana Dinapoli; Antonello Vidiri; Alessandra Fabi; Andrea Pace; Alfredo Pompili; Carmine Maria Carapella; Tonino Cantelmi
Journal:  J Neurooncol       Date:  2014-05-01       Impact factor: 4.130

3.  Affective symptoms and determinants of health-related quality of life in Mexican people with epilepsy.

Authors:  Carlos R Camara-Lemarroy; Mariana Hoyos; Beatriz E Ibarra-Yruegas; Marco A Díaz-Torres; Rolando De León
Journal:  Neurol Sci       Date:  2017-07-25       Impact factor: 3.307

4.  Prospective and longitudinal long-term employment outcomes after resective epilepsy surgery.

Authors:  Anna Edelvik; Roland Flink; Kristina Malmgren
Journal:  Neurology       Date:  2015-09-25       Impact factor: 9.910

5.  The Burden of Severely Drug-Refractory Epilepsy: A Comparative Longitudinal Evaluation of Mortality, Morbidity, Resource Use, and Cost Using German Health Insurance Data.

Authors:  Adam Strzelczyk; Claudia Griebel; Wolfram Lux; Felix Rosenow; Jens-Peter Reese
Journal:  Front Neurol       Date:  2017-12-22       Impact factor: 4.003

6.  Investigation of the Roles of New Antiepileptic Drugs and Serum BDNF Levels in Efficacy and Safety Monitoring and Quality of Life: A Clinical Research.

Authors:  Meral Demir; Emel O Akarsu; Hava O Dede; Nerses Bebek; Sevda O Yıldız; Betül Baykan; Ahmet G Akkan
Journal:  Curr Clin Pharmacol       Date:  2020

7.  Health-related quality of life in epilepsy patients receiving anti-epileptic drugs at National Referral Hospitals in Uganda: a cross-sectional study.

Authors:  Anne M Nabukenya; Joseph K B Matovu; Fred Wabwire-Mangen; Rhoda K Wanyenze; Fredrick Makumbi
Journal:  Health Qual Life Outcomes       Date:  2014-04-12       Impact factor: 3.186

8.  Incidence, Risk Factors and Consequences of Epilepsy-Related Injuries and Accidents: A Retrospective, Single Center Study.

Authors:  Laurent M Willems; Nina Watermann; Saskia Richter; Lara Kay; Anke M Hermsen; Susanne Knake; Felix Rosenow; Adam Strzelczyk
Journal:  Front Neurol       Date:  2018-06-15       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.